Eli Lilly’s $3.8 Billion Bet

The Timing Is Not Incidental

The timing isn’t accidental. Johnson & Johnson’s esketamine nasal spray, Spravato, has quietly become a commercial proof of concept — a ketamine-derived, Schedule III psychedelic-adjacent drug now annualizing close to $2 billion in sales for major depressive disorder and depression with suicidal ideation. Spravato demonstrated that a dissociative-acting molecule administered under clinical supervision could clear FDA approval, generate durable reimbursement, and scale into a real commercial franchise rather than a boutique therapy. It gave every pharma business-development team a template, and a revenue number, to point to internally when arguing for entry into the space.

Regulatory Hurdles And Tailwinds

Regulatory tailwinds have moved just as fast. Compass Pathways has posted back-to-back positive Phase 3 results for COMP360, its synthetic psilocybin program: COMP005 in mid-2025 and COMP006 in early 2026, the latter now showing durability out to six months. Compass has already begun a rolling NDA submission, with completion targeted for the fourth quarter of 2026 and a possible U.S. launch in the first half of 2027 — potentially the first “classic” psychedelic ever approved for a psychiatric indication.

Momentum accelerated further after President Trump’s April 2026 executive order directing federal agencies to speed up review of psychedelic therapies; the FDA followed within a week by issuing National Priority Vouchers to three psychedelic programs, compressing standard review timelines from ten-to-twelve months down to as little as one or two.

How Definium Therapeutics Fits Into The Landscape

Definium Therapeutics added its own data point in June, 2026, reporting that a single 100-microgram dose of its LSD-derived compound, DT120, produced an 8.1-point placebo-adjusted improvement on the MADRS depression scale at six weeks in the Phase 3 Emerge trial, with effect persisting at twelve weeks. Analysts at Jefferies called the magnitude “profound” and noted it appeared to outperform not only approved antidepressants but Spravato and Compass’s psilocybin data as well, on cross-trial comparisons that should be read cautiously given differing trial designs.

Asked how those results position Definium to help the tens of millions of Americans living with depression and anxiety, Chief Medical Officer Dan Karlin, M.D., a board certified psychiatrist, framed it as a failure of the existing standard of care. “We have more than 50 million adults in the U.S. living with generalized anxiety disorder (GAD) and major depressive disorder (MDD). The standard of care is failing them,” emphasized Karlin. “Despite dedicated professionals diligently prescribing medications based on the best scientific evidence, patients generally must wait weeks to see if any given medication will provide relief. Frustratingly, they may experience only partial response, fail to find sustained relief, and face persistent side effects.”

Karlin described Definium’s approach as psychedelics “revisited through a modern lens,” combining advances in neuroscience with the clinical rigor needed to build an evidence base for regulators and clinicians alike. He pointed beyond Emerge to the company’s broader Phase 3 slate — Ascend, Voyage, and Panorama, plus a newly announced Haven trial in PTSD — as evidence that DT120 ODT could become “a versatile, evidence-based solution across the most common mental health disorders.”

Pressed on how Definium sees its long-term position in MDD and GAD, Karlin was direct about the scale of unmet need and the work still ahead. “Simply put, the current standard of care isn’t enough for many people with GAD and MDD,” he said. “We’re applying modern rigor to psychedelics, specifically LSD. We believe our pharmaceutically optimized form of LSD, DT120 ODT, will be able to help patients address the underlying cause of disease versus simply masking symptoms.” Karlin noted that Definium is now turning to the FDA to determine how and when DT120 ODT can be safely administered, while working in parallel on reimbursement pathways — a reminder that clinical data alone doesn’t guarantee patients will be able to access a therapy once it’s approved.

Does The Spravato Model Still Have Validity?

Does the field follow the Spravato model? Mostly, yes — and that matters for how investors and clinicians should think about scalability. Every serious late-stage candidate in this space (BPL-003, COMP360, DT120) is being developed as an in-clinic, monitored, single- or limited-dose administration paired with psychological support, not a take-home pill. That’s structurally different from a conventional oral antidepressant business, and it caps how quickly volume can scale: each dosing session requires a trained clinician, a monitored space, and several hours of patient time. Spravato’s growth curve shows this model can scale into a multibillion-dollar franchise, but it scales more like an infusion-therapy or interventional-psychiatry business than like a pharmacy-dispensed pill. The upside is durability — a single dose of DT120 held up for twelve weeks, and COMP360 showed benefit out to six months — which changes the reimbursement math by reducing chronic daily-pill utilization in favor of periodic in-clinic sessions. The bottleneck isn’t demand; it’s infrastructure — the number of clinics, trained prescribers, and monitored treatment bays that can deliver the sessions safely at scale, the same constraint that has shaped Spravato’s rollout for six years.

The roster of players now spans a spectrum of maturity and ownership. AtaiBeckley is now owned by Eli Lilly, with BPL-003 aimed at TRD; Phase 3 readouts aren’t expected until 2029, so Lilly is paying up front for a still-unproven late-stage asset, wagering on class effect from J&J’s and Compass’s data.

Srinivas Rao, M.D PhD, AtaiBeckley’s co-founder and CEO, has described the company’s ambition as building “a differentiated and diversified pipeline of next-generation psychedelic-based therapies” spanning the full range of mood and anxiety disorders, with a treatment profile — rapid onset, durable benefit, and administration that fits real-world care settings — that he says patients and clinicians have long been seeking.

Rao noted that BPL-003 has already received FDA Breakthrough Therapy Designation and is designed to fit within roughly a two-hour in-clinic window, deliberately built to align with existing interventional-psychiatry workflows rather than the longer sessions associated with earlier psychedelic therapies. He pointed to two other programs moving through the pipeline behind BPL-003: VLS-01, an oral transmucosal DMT film built around that same short in-clinic model, which finished dosing its Phase 2b Elumina study in July 2026 and could advance to Phase 3 in MDD later this year; and EMP-01, an oral R-MDMA tablet for social anxiety disorder that posted positive Phase 2 results in April 2026. “We believe the mental health treatment landscape is approaching an inflection point,” Rao said, one where treatment moves “beyond chronic symptom management toward meaningful, lasting improvements for patients.”

The Regulatory Front-Runners

Meanwhile, Compass Pathways is the regulatory front-runner, closest to an actual NDA filing and a 2027 launch if the FDA and DEA cooperate, and arguably the most obvious remaining independent target for a large-cap acquirer that wants a first-mover psilocybin franchise rather than a molecule still years from Phase 3 completion.

Definium Therapeutics is now running three separate Phase 3 programs — MDD, GAD, and a second confirmatory MDD trial called Ascend due in 2027 — and its “best-in-class” efficacy claims and Catalent-partnered fast-dissolve formulation make it a plausible next acquisition target, particularly for a company that missed the Lilly or AbbVie deals.

Gilgamesh Pharmaceuticals is already partially absorbed, having sold its lead candidate to AbbVie for up to $1.2 billion, a template for smaller psychedelic biotechs to monetize a single high-value asset rather than build full commercial infrastructure themselves. And Johnson & Johnson remains the incumbent rather than a target, with Spravato serving as the commercial and regulatory benchmark every newer entrant is measured against.

If the pattern of the last year holds — AbbVie/Gilgamesh in August 2025, Lilly/AtaiBeckley in July 2026 — Compass Pathways is the name most frequently floated by Wall Street as the next acquisition candidate, given its regulatory lead and de-risked Phase 3 package; a deal could plausibly be struck before or shortly after an FDA approval decision, which the company now expects in late 2026 or early 2027.

Key Predictions Based On Prior Signals

Definium is arguably earlier-stage risk but has generated the strongest efficacy claims of 2026, which historically has been enough to draw suitor interest even ahead of a second pivotal readout. Karlin, for his part, framed the Lilly deal as validation for the whole category rather than a signal that Definium needs to follow suit immediately. “The acquisition reinforces the growing recognition of the long-term potential of psychedelic medicines,” he said. “Additional investment that advances scientific rigor and strengthens the foundation for clinical implementation will help accelerate patient access. We remain highly confident in the strength and differentiation of our DT120 (lysergide) oral dissolving tablet (ODT) clinical data in Major Depressive Disorder and Generalized Anxiety Disorder, and the extraordinary opportunity ahead of us.” As of July 2026, however, no acquisition talks involving Compass or Definium have been publicly confirmed by either company; both remain independent, and any deal timing is speculative rather than reported.

One constraint the Spravato comparison doesn’t fully capture is scheduling. Ketamine and Esketamine were never classic psychedelics under the Controlled Substances Act (CSA) in the same sense psilocybin and LSD are. Even if COMP360 or DT120 clears FDA approval, DEA rescheduling is a separate and sequential step. Compass has been explicit that its 2027 launch target is contingent on rescheduling happening on a compatible timeline.

That adds a second regulatory gate most oral-drug launches don’t face, and it’s a variable that large-pharma acquirers have to underwrite alongside ordinary clinical and commercial risk. It’s also why the Trump administration’s April 2026 executive order and the FDA’s subsequent National Priority Vouchers mattered as much as any single trial readout: they signal that the federal apparatus governing both approval and scheduling is now aligned in the same direction, which is precisely the kind of policy risk reduction that makes a $3.8 billion acquisition committee comfortable.

What Lilly’s move really signals isn’t that psychedelics have “arrived” scientifically — Compass’s and Definium’s data were doing that work already — but that the commercial and regulatory risk has fallen enough for large-cap pharma balance sheets to underwrite it.

Bloomberg Intelligence estimates the psychedelic-treatment market at roughly $7 billion in sales by 2032, a number that would have seemed fanciful five years ago when psilocybin and LSD were federally scheduled curiosities with essentially no institutional capital behind them.

The field is not going to scale like a blockbuster oral drug; it’s going to scale like Spravato has — clinic by clinic, prescriber by prescriber — but with a growing list of billion-dollar acquirers now willing to fund that buildout.

Emily Sofin, B.S., contributed to this article.